Project Grant R43HD109101
Award Date 4/6/22
Completion Date 3/31/23
Dollars Obligated $597K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Frisco, TX 75034, USA
Similar Awards
- This Project Grant award, provided by the National Institute of Child Health and Human Development (NICHD), is funding a Phase 1 clinical trial to evaluate the safety and pharmacokinetics of a novel contraceptive and microbicidal vaginal gel developed by Yaso Therapeutics Incorporated. The $545,966 award supports the first-in-human clinical assessment of the "YASO-GEL" product, which contains the active ingredient polyphenylene carboxymethylene sodium salt (PPCM). In addition to...
- This $474,946 Project Grant awarded on February 1, 2025 by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) aims to develop a novel, multipurpose device for female-initiated, non-hormonal contraception. The key products to be delivered under this grant include: Design and prototyping of a dual-compartment vaginal device that enables women to administer a bioresponsive polymer fiber mat...
- The National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research Federal Grant Program (CFDA 93.865), awarded a $518,754 project grant to Magee-Womens Research Institute and Foundation. The goal of this project is to develop a bioadhesive vaginal film that can provide sustained release of contraceptive and antiviral monoclonal antibodies for 3-7 days. The film is intended to offer women a discreet, low-cost, and convenient...
- This $1,130,880 Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports the development of a fast-dissolving, non-hormonal contraceptive tablet (product code MM008) by Mucommune LLC, a biopharmaceutical company in Durham, North Carolina. The grant aims to formulate Mucommune's proprietary anti-sperm monoclonal antibodies into a...
- This Project Grant award of $380,692 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research Federal Grant Program (CFDA 93.865), is for the development of an ultrapotent anti-sperm antibody construct for a non-hormonal contraceptive. The project aims to create a novel intravaginal ring product that releases an anti-sperm antibody to agglutinate and trap sperm, thereby preventing pregnancy. The award supports the...
- The U.S. National Institute of Child Health and Human Development (NICHD) awarded a $399,999 Project Grant to Sacyl Pharmaceuticals, Inc. under the Child Health and Human Development Extramural Research program (CFDA 93.865) to advance the development of a novel on-demand, non-hormonal male contraceptive towards Investigational New Drug (IND) enablement. The project aims to develop small molecule inhibitors of soluble adenylyl cyclase (ADCY10; SAC) in sperm, which has been genetically and...
- The National Institute of Child Health and Human Development (NICHD), through the Child Health and Human Development Extramural Research program (CFDA 93.865), awarded a $328,496 Project Grant to Pelva Health Corporation to develop a non-pharmaceutical hydrogel film and applicator delivery system to mitigate pain experienced during sexual intercourse by women with gynecological conditions such as vulvodynia and vestibulodynia. The goal is to create a force dissipating hydrogel film that can...
- This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research Federal Grant Program (CFDA 93.865), provides $1,295,474 to Yale University to conduct a prospective two-year study on the use of the etonogestrel (ENG) contraceptive implant when inserted at an alternative subdermal scapular site. The study aims to collect long-term pharmacokinetic and pharmacodynamic data on the ENG implant...
- The National Institute of Child Health and Human Development (NICHD) awarded a $383,114 Small Business Innovation Research (SBIR) Phase I project grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to Venova Technologies Inc., a women-led and minority-led medical device startup company. The grant funds the development of a novel, non-hormonal, long-acting female contraceptive device designed to address the critical unmet need for birth control options without hormonal...
- This $747,000 Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will fund research to determine the effects of pre-exposure prophylactic (PrEP) drugs on female genital HIV infection and women's reproductive health. The research will focus on understanding how PrEP impacts the female reproductive tract microenvironment and any potential...